Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a ...

Abstract: Conventional microarray-based biosensors can only detect a limited number of organisms, and adding sensor capabilities requires re-engineering of reagents and devices to detect the presence ...

Abstract: Oligo DNA microarrays are fabricated through in-situ chemical synthesis. Contact and fluid dynamics all contribute to this process. To produce high quality oligo DNA microarrays, it is ...